A provision in LB732 creates immediate compliance obligations and financial penalties for Nebraska health services that prescribe gender-related hormones to minors.
Most Nebraska health service owners haven't realized that LB732—a bill focused on the state's approach to gender-related medical care for minors—contains a provision with direct, immediate consequences for any practice, pharmacy, or telehealth provider currently prescribing cross-sex hormones or puberty blockers to patients under 18.
Section 4 of LB732, codified as Section 71-7305(2)(a) on page 7, bans health care practitioners in Nebraska from prescribing cross-sex hormones and puberty-blocking drugs to minors for the purpose of gender alteration. The law is effective on the date the act becomes law.
For practices already providing these treatments, there is a transition period: existing patients may continue treatment until January 1, 2027. After that date, all such prescriptions must cease.
This applies directly to:
Even if your practice does not currently advertise this service, if you have minor patients on these medications, the law applies to you.
Violations carry a civil penalty of $25,000 per violation. Because each prescription or dispensing act could constitute a separate violation, the exposure can accumulate quickly. Beyond financial penalties, violations may trigger professional discipline through the state licensing board, affecting your ability to practice.
For small practices and independent providers, a single enforcement action can create significant operational and financial strain.
Immediate steps: Review your current patient roster and medication records to identify any minors receiving cross-sex hormones or puberty blockers. If you have such patients, document them now.
For existing patients: You may continue treatment through January 1, 2027, but you should plan now for how you will manage the transition. This includes patient communication, medical record documentation, and coordination with patients and families on next steps before the deadline.
For new patients: As of the effective date, you cannot initiate new prescriptions of cross-sex hormones or puberty blockers to minors.
Documentation: Keep clear records of which patients are grandfathered under the transition period and when their treatment must end. This protects you if questions arise later.
If your practice operates across state lines or serves patients in multiple states, confirm that you understand how this Nebraska law applies to your specific operations.
The transition period through January 1, 2027, gives practices time to adjust, but only if you act now to understand your current exposure and plan accordingly. Waiting until late 2026 to address this will create unnecessary pressure and compliance risk.
This explainer is based on LB732, Section 4, Section 71-7305(2)(a). For detailed guidance specific to your practice structure and patient population, consult your legal counsel or professional association.